IsoRay, Inc. (ISR)


IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the sole producer of the Proxcelan™ Cesium-131 brachytherapy seed, used to treat prostate and other cancers. The Proxcelan™ seed offers a significantly shorter half-life than the two other isotopes commonly used for brachytherapy, which results in a substantially faster delivery of therapeutic radiation, lower probability of cancer cell survival and reduction of the longevity of common brachytherapy side effects (a)(b). IsoRay is based in Richland, Washington. More information is available about IsoRay at

Contact Information

350 Hills Street
Suite 106
Richland, WA 99352

tel: 509-375-1202
fax: 509-375-3473


Investor Relations



Exchange: AMEX
Industry: Medical Instruments & Supplies
Market Cap: $17.7M

The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.